Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.070
-0.060 (-2.82%)
Mar 11, 2026, 4:00 PM EDT - Market closed
Ovid Therapeutics Revenue
Ovid Therapeutics had revenue of $132.00K in the quarter ending September 30, 2025, a decrease of -23.70%. This brings the company's revenue in the last twelve months to $6.61M, up 945.89% year-over-year. In the year 2024, Ovid Therapeutics had annual revenue of $566.00K with 44.39% growth.
Revenue (ttm)
$6.61M
Revenue Growth
+945.89%
P/S Ratio
40.77
Revenue / Employee
$287,391
Employees
23
Market Cap
269.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
| Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
| Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
| Dec 31, 2021 | 208.38M | 195.77M | 1,551.57% |
| Dec 31, 2020 | 12.62M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 82.55M |
| Coherus Oncology | 42.17M |
| OmniAb | 18.67M |
| AC Immune | 5.48M |
| Orchestra BioMed Holdings | 2.82M |
| Silence Therapeutics | 559.00K |
| Abeona Therapeutics | 400.00K |
OVID News
- 14 days ago - Ovid Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha
- 2 months ago - Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) - GlobeNewsWire
- 3 months ago - Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - GlobeNewsWire
- 4 months ago - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Inc. - Special Call - Seeking Alpha
- 5 months ago - Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds - GlobeNewsWire
- 5 months ago - Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile - GlobeNewsWire